These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 7821330)
1. Dilemma in the treatment of Parkinson's disease with L-dopa. Kuno S Eur Neurol; 1994; 34 Suppl 3():17-9. PubMed ID: 7821330 [TBL] [Abstract][Full Text] [Related]
2. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
4. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Merello M; Nouzeilles MI; Arce GP; Leiguarda R Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878 [TBL] [Abstract][Full Text] [Related]
5. Treatment of Parkinson's disease: problems with a progressing disease. Rinne UK J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in pharmacological therapy of Parkinson's disease. Riederer P; Lange KW; Youdim MB Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582 [TBL] [Abstract][Full Text] [Related]
7. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Lees AJ; Tolosa E; Olanow CW Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030 [TBL] [Abstract][Full Text] [Related]
8. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room. Paul R; Borah A Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154 [TBL] [Abstract][Full Text] [Related]
9. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Mercuri NB; Bernardi G Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832 [TBL] [Abstract][Full Text] [Related]
10. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy. Fischer PA J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073 [TBL] [Abstract][Full Text] [Related]
11. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease]. Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759 [TBL] [Abstract][Full Text] [Related]
12. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677 [TBL] [Abstract][Full Text] [Related]
13. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Hely MA; Morris JG; Reid WG; Trafficante R Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331 [TBL] [Abstract][Full Text] [Related]
14. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment. Caraceni TA; Girotti F; Giovannini P; Parati E J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210 [TBL] [Abstract][Full Text] [Related]